...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International journal of antimicrobial agents >Lomefloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis
【24h】

Lomefloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis

机译：洛美沙星与环丙沙星治疗慢性细菌性前列腺炎

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

A total of 182 patients with chronic bacterial prostatitis (CBP) were recruited into this multicentre prospective, randomized clinical study. Of these, 93 were treated orally with lomefloxacin (LOMX) 400 mg once daily and 89 with ciprofloxacin (CIPX) 500 mg twice daily for 4 weeks. At 5-9 days 90/90 vs 86/86, at 4-6 weeks 82/83 vs 82/82, at 3 months 80/79 vs 78/75, and at 6 months 78/75 vs 75/72 patients aging from 18 to 70 years were evaluable bacteriologically/clinically according to a modified intention to treat evaluation. The most frequent pathogens were Escherichia coli, followed by staphylococci, enterococci and Proteus mirabilis. At 59 days, 4-6 weeks, 3 and 6 months after therapy the rates of eradication without superinfection per evaluable patients (100%) were 80, 72, 74, and 63% in the LOMX group and 84, 81, 82, and 72% in the CIPX group and (cure and improvement) rates were 98 vs 97%, 84 vs 90%, 86 vs 89%, and 81 vs 89%. There were no statistically significant differences (P < 0.05) between the results of the two treatment groups. Nine (5 vs 4) patients were withdrawn because of adverse events. From the bacteriological and clinical results including adverse events, the oral treatment of CBP over 4 weeks with LOMX 400 mg once daily was comparably effective and tolerable with that of CIPX 500 mg twice daily. (C) 2002 Elsevier Science B.V. and International Society of Chemotherapy. All rights reserved. [References: 26]
机译：总共182例慢性细菌性前列腺炎（CBP）患者被纳入该多中心前瞻性随机临床研究中。其中93例每天接受400 mg洛美沙星（LOMX）口服治疗，89例每天接受500 mg环丙沙星（CIPX）口服治疗4周。在5-9天时90/90 vs 86/86，在4-6周时82/83 vs 82/82，在3个月时80/79 vs 78/75，以及在6个月时78/75 vs 75/72患者衰老根据修改后的治疗意向，可以从细菌学/临床上评估18至70岁的儿童。最常见的病原体是大肠杆菌，其次是葡萄球菌，肠球菌和奇异变形杆菌。治疗后59天，4-6周，3和6个月，LOMX组中每位可评估患者（100％）的无超级感染的根除率分别为80％，72％，74％和63％，以及84、81、82和CIPX组的72％和（治愈和改善）率分别为98比97％，84比90％，86比89％和81比89％。两个治疗组的结果之间无统计学差异（P <0.05）。 9名（5比4）患者因不良事件而退出。从包括不良事件在内的细菌学和临床结果来看，每天4次LOMX 400 mg口服治疗CBP与每天两次CIPX 500 mg口服治疗具有相当的疗效和耐受性。 （C）2002 Elsevier Science B.V.和国际化学疗法学会。版权所有。 [参考：26]

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号